Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Anlotinib for High-Risk HCC After Resection
NCT04947371Phase 2Withdrawn
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Adverse events rate at 12 months. Planned start Dec 2018; status: withdrawn.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04947371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947371.